Gene Therapy Pioneer Jim Wilson Launches Franklin Biolabs, Expanding Genetic Medicine Services
Jim Wilson, Franklin Biolabs, Gene Therapy, Genetic Medicine Services, Rare Diseases, Adeno-Associated Viruses (AAVs)
FDA Declares End to Tirzepatide Shortage, Impacting Compounded Versions of Mounjaro and Zepbound
tirzepatide shortage, FDA, Mounjaro, Zepbound, compounded medications, GLP-1 drugs
Flagship’s Winning Streak Continues with Singapore R&D Partnership
Flagship, R&D collaboration, Singapore, biotech, innovation
Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy
340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
Frazier Replenishes Fund with $630 Million for Public Biotech Investments
Frazier, biotech fund, public biotechs, investment, biotechnology
Pharmaceutical Industry Faces Widespread Layoffs Amid Economic Pressures
pharmaceutical layoffs, economic pressures, biopharma industry, job cuts, restructuring efforts
WHO Approves First Mpox Diagnostic Test for Emergency Use: Expanding Global Access to Mpox Testing
WHO, mpox diagnostic test, emergency use, Abbott Molecular, Alinity m MPXV assay, global health emergency, public health efforts
Mendaera Secures $73M Series B Funding to Revolutionize Mainstream Medical Procedures with Robotics and AI
Mendaera, Series B funding, robotics, AI, medical procedures, healthcare technology, Threshold Ventures
Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma
TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses